Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Gene Expressions of Nitric Oxide Synthase and Matrix Metalloproteinase-2 in Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment

  • Koo, Hee-Sun (Department of Pediatrics, School of Medicine, Ewha Womans University) ;
  • Kim, Kwan-Chang (Department of Thoracic and Cardiovascular Surgery, School of Medicine, Ewha Womans University) ;
  • Hong, Young-Mi (Department of Pediatrics, School of Medicine, Ewha Womans University)
  • Published : 2011.02.28
⟨ Previous Next ⟩

Abstract

Background and Objectives: Nitric oxide (NO) is a major endothelium dependent vasomediator and growth inhibitor. NO synthesis is catalyzed by endothelial nitric oxide synthase (eNOS), and NO can also produce peroxynitrite, which activates matrix metalloproteinases (MMPs). The purpose of this study was to determine the gene expression of eNOS and MMP-2 in the lungs of a rat model of pulmonary hypertension after bosentan treatment. Materials and Methods: Six-week-old male Sprague-Dawley rats were treated as follows: control group, subcutaneous (sc) injection of saline; monocrotaline (MCT) group, sc injection of MCT (60 mg/kg); and bosentan group, sc injection of MCT (60 mg/kg) plus 20 mg/day bosentan orally. The rats were sacrificed after 1, 5, 7, 14 and 28 days. Results: The right ventricle/(left ventricle+septum) ratio significantly increased in the MCT group compared to the control group on day 14 and 28. The expression of eNOS messenger ribonucleic acid was significantly increased in the MCT group compared to the control group on day 28. MMP-2 gene expression was significantly increased in the MCT-treated rats compared to the control group on day 5 and 28. Following bosentan treatment to reduce pulmonary hypertension, the expression levels of MMP-2 gene were significantly decreased on day 7 and 28. eNOS and tissue inhibitor of MMPs genes were also significantly decreased on day 28 after bosentan treatment. Conclusion: These results suggest that elevated eNOS expression may be responsible for MMP-2 activation. The causal relationship between eNOS and MMP-2 and their role in pulmonary hypertension require further investigations.

Keywords

References

  1. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 2002;277:44085-92. https://doi.org/10.1074/jbc.M205934200
  2. Everett AD, Le Cras TD, Xue C, Johns RA. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol 1998;274:L1058-65.
  3. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358: 1119-23. https://doi.org/10.1016/S0140-6736(01)06250-X
  4. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med 2006;231:967-73.
  5. Frisdal E, Gest V, Vieillard-Baron A, et al. Gelatinase expression in pul-monary arteries during experimental pulmonary hypertension. Eur Respir J 2001;18:838-45. https://doi.org/10.1183/09031936.01.00084601
  6. Lepetit H, Eddahibi S, Fadel E, et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:834-42. https://doi.org/10.1183/09031936.05.00072504
  7. Morrel NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl): S20-31.
  8. Lim KA, Shim JY, Cho SH, Kim KC, Han JJ, Hong YM. Effect of endothelin receptor blockade on monocrotaline-induced pulmonary hypertension in rats. Korean J Pediatr 2009;52:689-95. https://doi.org/10.3345/kjp.2009.52.6.689
  9. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993; 73:887-97. https://doi.org/10.1161/01.RES.73.5.887
  10. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and be-raprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-8. https://doi.org/10.1164/rccm.200303-346OC
  11. Lim KY, Kim KC, Cho MS, Lee BR, Kim HS, Hong YM. Gene expression of endothelin-1 and endothelin receptor A on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Cir J 2010;40:459-64. https://doi.org/10.4070/kcj.2010.40.9.459
  12. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000;80:1337-72.
  13. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21. https://doi.org/10.1056/NEJM199507273330403
  14. Komai H, Naito Y, Aimi Y, Kimura H. Nitric oxide synthase expression in lungs of pulmonary hypertensive patients with heart disease. Cardiovasc Pathol 2001;10:29-32. https://doi.org/10.1016/S1054-8807(00)00063-6
  15. Kim MY, Kim YK, Jung YW, Kim WT, Kwon TH, Lee DS. The protective effect of simvastatin on monocrotaline-induced pulmonary hypertension in rats. Korean Circ J 2008;38:313-9. https://doi.org/10.4070/kcj.2008.38.6.313
  16. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Ch-aracterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006;291:H2424-30. https://doi.org/10.1152/ajpheart.00369.2006
  17. Umar S, Hessel M, Steendijk P, et al. Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract 2007;203:863-72. https://doi.org/10.1016/j.prp.2007.08.006
  18. Tyler RC, Muramatsu M, Abman SH, et al. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol 1999;276:L297-303.
  19. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol 1997;272:H806-13.
  20. Mathew R, Yuan N, Rosenfeld L, Gewitz MH, Kumar A. Effects of mo-nocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs. Heart Dis 2002;4:152-8. https://doi.org/10.1097/00132580-200205000-00004
  21. Chou TF, Wu MS, Chien CT, Yu CC, Chen CF. Enhanced expression of nitric oxide synthase in the early stage after increased pulmonary blood flow in rats. Eur J Cardiothorac Surg 2002;21:331-6. https://doi.org/10.1016/S1010-7940(01)01129-0
  22. Dai ZK, Tan MS, Chai CY, Chen IJ, Jeng AY, Wu JR. Effects of increased pulmonary flow on the expression of endothelial nitric oxide synthase and endothelin-1 in the rat. Clin Sci 2002;103(Suppl 48): 289S-93S. https://doi.org/10.1042/CS103S289S
  23. Black SM, Fineman JR, Steinhorn RH, Bristow J, Soifer SJ. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol 1998;275:H1643-51.
  24. Xue C, Johns RA. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension 1996;28:743-53. https://doi.org/10.1161/01.HYP.28.5.743
  25. Le Cras TD, Xue C, Rengasamy A, Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol 1996;270:L164-70.
  26. Resta TC, Chicoine LG, Omdahl JL, Walker BR. Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am J Physiol 1999;276:H699-708.
  27. Le Cras TD, McMurtry IF. Nitric oxide production in the hypoxic lung. Am J Physiol Lung Cell Mol Physiol 2001;280:L575-82. https://doi.org/10.1152/ajplung.2001.280.4.L575
  28. Fagan KA, Morrissey B, Fouty BW, et al. Upregulation of nitric oxide synthase in mice with severe hypoxia-induced pulmonary hypertension. Respir Res 2001;2:306-13. https://doi.org/10.1186/rr74
  29. Mukhopadhyay S, Xu F, Sehgal PB. Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging. Am J Phy-siol Heart Circ Physiol 2007;292:H1373-89. https://doi.org/10.1152/ajpheart.00990.2006
  30. Wang QD, Li XS, Pernow J. The nonpeptide endothelin receptor antagonist bosentan enhances myocardial recovery and endothelial function during reperfusion of the ischemic rat heart. J Cardiovasc Pharmacol 1995;26(Suppl 3):S445-7. https://doi.org/10.1097/00005344-199526003-00131
  31. Winkler MK, Foldes JK, Bunn RC, Fowlkes JL. Implications for matrix metalloproteinases as modulators of pediatric lung disease. Am J Physiol Lung Cell Mol Physiol 2003;284:L557-65. https://doi.org/10.1152/ajplung.00195.2002

Cited by

  1. Effects of Bosentan Treatment on Angiotensin Converting Enzyme in Monocrotaline Induced Pulmonary Hypertension Rats vol.17, pp.1, 2011, https://doi.org/10.5646/jksh.2011.17.1.28
  2. Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension vol.306, pp.12, 2011, https://doi.org/10.1152/ajplung.00279.2013
  3. Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling vol.308, pp.10, 2011, https://doi.org/10.1152/ajpheart.00864.2014
  4. Modafinil improves monocrotaline-induced pulmonary hypertension rat model vol.80, pp.1, 2011, https://doi.org/10.1038/pr.2016.38
  5. Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis vol.6, pp.2, 2011, https://doi.org/10.3892/br.2016.832
  6. Microarray Analysis in Pulmonary Hypertensive Rat Heart after Simvastatin Treatment vol.41, pp.3, 2018, https://doi.org/10.12771/emj.2018.41.3.53
  7. Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model vol.49, pp.9, 2011, https://doi.org/10.4070/kcj.2019.0006
  8. Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension vol.13, pp.None, 2011, https://doi.org/10.2147/jep.s236743
  9. The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study vol.21, pp.1, 2011, https://doi.org/10.1186/s12872-021-02424-5
  10. Association of 5-aminolevulinic acid with intraoperative hypotension in malignant glioma surgery vol.37, pp.None, 2011, https://doi.org/10.1016/j.pdpdt.2021.102657